Release date: 2017-04-28
It sounds like science fiction:
A hat-like device that fights tumors by releasing low- and medium-frequency alternating electric fields and prolongs the lifespan of patients with deadly brain tumors.
It is a portable non-invasive device developed by Novocure, a cancer treatment company in the United States, Optune. By releasing Tumor Treating Fields (TTFields), Optune is able to inhibit cancer cell replication for anti-tumor purposes.
In 2015, Optune was approved by the US FDA for the treatment of newly diagnosed glioblastoma (GBM) adult patients in combination with temozolomide. Optune is the first approved treatment for patients with newly diagnosed glioblastoma who have a longer survival period in more than a decade.
At present, Optune has been marketed in the United States, Germany, Switzerland and Japan for the treatment of adult patients with glioblastoma multiforme, and can also be combined with surgery, radiotherapy and chemotherapy to prevent tumor recurrence.
How Optune works 
Image source: Novocure
Optune is a tumor treatment electric field therapy. With a portable, non-invasive medical device, it creates a low-intensity alternating electric field inside the tumor. This electric field can inhibit cell division (interfering with the way the chromosomes are arranged) and cause cancer cells to die. Compared to normal brain cells, tumor cells divide indefinitely, so theoretically this device can eliminate bad cells.
Optune's power supply is small enough to hold a patient's pocket for easy carrying. Patients wear Optune and need to shave their hair, but they can wear a hat again. Every day, patients need at least 18 hours of Optune treatment, they only feel a slight heat, and there is no additional discomfort.
Latest clinical trial results
At the recent American Association for Cancer Research meeting, Optune's latest large clinical trial data was published: compared to conventional chemotherapy (5%), many patients with glioblastoma (13%) are receiving Optune and conventional methods. After treatment, the survival period is more than 5 years.
As early as 2011, Optune had already conducted clinical research. Although it did not significantly improve the survival rate of patients at the time, it was able to slow down the symptoms and was superior to traditional chemotherapy.
A subsequent clinical trial (2014) was used to treat newly diagnosed patients. The results showed that approximately half of the patients (695) had a longer overall survival than those who did not receive Optune.
However, many doctors remain skeptical about the "cancer treatment electric field" and believe that it is not a treatment. In this regard, Professor Roger Stupp, the head of the latest clinical trial and brain tumor specialist at Northwestern University in Chicago, said: "This is a treatment that breaks traditional thinking, so many doctors have difficulty understanding it or don't think it works."
The latest clinical data show that after Optune combined with drug treatment, the median survival of patients reached 21 months, the two-year survival rate was 43%, the 3-year survival rate was 26%, and the 5-year survival rate was 13%; Patients who received only medication had a median survival of 16 months, a two-year rate of 31%, a 3-year survival rate of 16%, and a 5-year survival rate of 5%.
Moreover, Optune is safely treated in combination with chemical agents, and its most common adverse reactions include weakness, fatigue, and mild to moderate skin irritation.
Glioblastoma is the most common brain tumor, and there has been no significant improvement in medical treatment for more than a decade. Dr. Andrew Lassman, chief scientist of brain tumors at Columbia University Medical Center, said: "This result is undoubtedly an improvement." The latest National Comprehensive Cancer Center guidelines in the United States include Optune as a means of treating brain-filled tumors.
price
In addition to efficacy, Optune also faces a big problem – the average cost of an average of $700 per day ($21,000 per month). However, Novocure CEO Bill Doyle said they have never rejected a patient, whether or not he has insurance.
Moreover, he said that this high price is not without reason: medical equipment for 17 years of laboratory development, animal and clinical trial cycles, patients need to replace multiple disposable accessories every week, and each All patients need to be equipped with professional medical staff.
Patient experience 
On March 29th, Joyce Endresen at work wore Optune equipment (to treat brain tumors). In December 2014, she was diagnosed with glioblastoma. (AP Photo)
Two years ago, Joyce Endresen was diagnosed with glioblastoma. After receiving Optune treatment, in addition to every two months of review, she still works. Now, Endresen has not detected cancer for 2 consecutive years. Unlike other patients who resisted, Joyce Endresen is proud to wear Optune. She said: "Because of the emergence of this device, I can continue to work now."
Source: Bio-Exploration
We have not only conventional Honey but also organic honey, which have certified by BCS German. The main type is organic polyflora honey, organic acacia honey and organic vitex honey, which come from the northeast of China and Northwest of China. We supply transaction issued by BCS GERMAN for each lot when export.
Organic Polyflora Honey,Organic Acacia Honey,Organic Vitex Honey,Bee Honey,Vitex Honey
Easy Food (Jiaxing) Co., Ltd. , https://www.jxeasyfood.com